{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:16:07Z","timestamp":1794636967607,"version":"4.9.1"},"reference-count":83,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association Career Development Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","award":["K23HL159279"],"award-info":[{"award-number":["K23HL159279"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK115392"],"award-info":[{"award-number":["R01 DK115392"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL153004"],"award-info":[{"award-number":["R01 HL153004"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK16618"],"award-info":[{"award-number":["R01 DK16618"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL155834"],"award-info":[{"award-number":["R01 HL155834"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation","award":["1R01HL15583401"],"award-info":[{"award-number":["1R01HL15583401"]}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Labor Sciences Research","award":["23FC1041"],"award-info":[{"award-number":["23FC1041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Primary aldosteronism is a form of low-renin hypertension characterized by dysregulated aldosterone production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the contributions of renin-independent aldosteronism and ACTH-mediated aldosteronism in individuals with a low-renin phenotype representing the entire continuum of blood pressure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design\/Participants<\/jats:title>\n                    <jats:p>Human physiology study of 348 participants with a low-renin phenotype with severe and\/or resistant hypertension, hypertension with hypokalemia, elevated blood pressure and stage I\/II hypertension, and normal blood pressure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>4 international centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions\/Main Outcome Measures<\/jats:title>\n                    <jats:p>The saline suppression test (SST) to quantify the magnitude of renin-independent aldosteronism; dexamethasone suppression and ACTH-stimulation tests to quantify the magnitude of ACTH-mediated aldosteronism; adrenal venous sampling to determine lateralization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was a continuum of nonsuppressible and renin-independent aldosterone production following SST that paralleled the magnitude of the blood pressure continuum and transcended conventional diagnostic thresholds. In parallel, there was a full continuum of ACTH-mediated aldosteronism wherein post-SST aldosterone levels were strongly correlated with ACTH-stimulated aldosterone production (r = 0.75, P &amp;lt; .0001) and nonsuppressible aldosterone production postdexamethasone (r = 0.40, P &amp;lt; .0001). Beyond participants who met the criteria for primary aldosteronism (post-SST aldosterone of \u226510\u2005ng\/dL or \u2265277 pmol\/L), the continuum of nonsuppressible and renin-independent aldosterone production persisted below this diagnostic threshold, wherein 15% still had lateralizing aldosteronism amenable to surgical adrenalectomy and the remainder were treated with mineralocorticoid receptor antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the context of a low-renin phenotype, there is a continuum of primary aldosteronism and dysregulated aldosterone production that is prominently influenced by ACTH. A large proportion of individuals with low renin may benefit from aldosterone-directed therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae145","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:34:06Z","timestamp":1709631246000},"page":"2220-2232","source":"Crossref","is-referenced-by-count":72,"title":["The Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study"],"prefix":"10.1210","volume":"109","author":[{"given":"Wasita W","family":"Parksook","sequence":"first","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Endocrinology and Metabolism, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok 10330 ,","place":["Thailand"]},{"name":"Division of General Internal Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok 10330 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer M","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Omata","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Tohoku University Hospital , Sendai 980-8576 ,","place":["Japan"]},{"name":"Division of Nephrology, Rheumatology and Endocrinology, Tohoku University , Sendai 980-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Tezuka","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Tohoku University Hospital , Sendai 980-8576 ,","place":["Japan"]},{"name":"Division of Nephrology, Rheumatology and Endocrinology, Tohoku University , Sendai 980-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1873-7388","authenticated-orcid":false,"given":"Yoshikiyo","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Tohoku University Hospital , Sendai 980-8576 ,","place":["Japan"]},{"name":"Division of Nephrology, Rheumatology and Endocrinology, Tohoku University , Sendai 980-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Rheumatology and Endocrinology, Tohoku University , Sendai 980-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Tsai","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Niebuhr","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Milks","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Moore","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Honzel","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Auchus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48104 ,","place":["USA"]},{"name":"Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School , Ann Arbor, MI 48104 ,","place":["USA"]},{"name":"Endocrinology & Metabolism Section, Medicine Service, LTC Charles S. Kettles VA Medical Center , Ann Arbor, MI 48104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat","family":"Sunthornyothin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok 10330 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina F","family":"Turcu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":false,"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2026041420191762200_dgae145-B1","volume-title":"Global Report on Hypertension: the Race Against a Silent Killer","author":"(WHO) WHO","year":"2023"},{"issue":"10304","key":"2026041420191762200_dgae145-B2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Collaboration NCDRF","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2026041420191762200_dgae145-B3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ajh.2011.216","article-title":"Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system","volume":"25","author":"Sim","year":"2012","journal-title":"Am J Hypertens"},{"issue":"4","key":"2026041420191762200_dgae145-B4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/cen.13741","article-title":"Diagnostic approach to low-renin hypertension","volume":"89","author":"Monticone","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026041420191762200_dgae145-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjhyper.2003.08.015","article-title":"Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients","volume":"17","author":"Alderman","year":"2004","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026041420191762200_dgae145-B6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/ijms19020546","article-title":"The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor","volume":"19","author":"Baudrand","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026041420191762200_dgae145-B7","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ajh\/hpt091","article-title":"Bimodal aldosterone distribution in low-renin hypertension","volume":"26","author":"Adlin","year":"2013","journal-title":"Am J Hypertens"},{"issue":"4","key":"2026041420191762200_dgae145-B8","first-page":"661","article-title":"Primary aldosteronism","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"2026041420191762200_dgae145-B9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.1964.03070160046009","article-title":"Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension","volume":"190","author":"Conn","year":"1964","journal-title":"JAMA"},{"issue":"4","key":"2026041420191762200_dgae145-B10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jama.1985.03350280114034","article-title":"Landmark article oct 19, 1964: suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By jerome W. Conn, edwin L. Cohen and david R. Rovner","volume":"253","author":"Conn","year":"1985","journal-title":"JAMA"},{"issue":"1","key":"2026041420191762200_dgae145-B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lab.2004.11.016","article-title":"The 50th anniversary of the identification of primary aldosteronism: a retrospective of the work of jerome W. Conn","volume":"145","author":"Schteingart","year":"2005","journal-title":"J Lab Clin Med"},{"issue":"6","key":"2026041420191762200_dgae145-B12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archinte.1972.03650060047008","article-title":"Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity","volume":"130","author":"Adlin","year":"1972","journal-title":"Arch Intern Med"},{"issue":"7908","key":"2026041420191762200_dgae145-B13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(75)91814-0","article-title":"Letter: plasma-renin and blood-pressure","volume":"1","author":"Adlin","year":"1975","journal-title":"Lancet"},{"issue":"9\u201310","key":"2026041420191762200_dgae145-B14","first-page":"1869","article-title":"The salivary sodium\/potassium ratio in hypertension: relation to race and plasma renin activity","volume":"4","author":"Adlin","year":"1982","journal-title":"Clin Exp Hypertens A"},{"issue":"1","key":"2026041420191762200_dgae145-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-72-1-9","article-title":"Suppressed plasma renin activity in essential hypertension. Roles of plasma volume, blood pressure, and sympathetic nervous system","volume":"72","author":"Jose","year":"1970","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026041420191762200_dgae145-B16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archinte.1972.03650060041007","article-title":"The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone","volume":"130","author":"Carey","year":"1972","journal-title":"Arch Intern Med"},{"issue":"2","key":"2026041420191762200_dgae145-B17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.1979.03290280031022","article-title":"Renin profiling for diagnosis and treatment of hypertension","volume":"241","author":"Laragh","year":"1979","journal-title":"JAMA"},{"issue":"2","key":"2026041420191762200_dgae145-B18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archinte.1974.00320140043004","article-title":"Low-renin hypertension. Restoration of normotension and renin responsiveness","volume":"133","author":"Spark","year":"1974","journal-title":"Arch Intern Med"},{"issue":"9","key":"2026041420191762200_dgae145-B19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF01476798","article-title":"Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading","volume":"58","author":"Helber","year":"1980","journal-title":"Klin Wochenschr"},{"issue":"2","key":"2026041420191762200_dgae145-B20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/jcem-39-2-247","article-title":"Low renin, \u201cnormal\u201d aldosterone and hypertension: circadian rhythm of renin, aldosterone, cortisol and growth hormone","volume":"39","author":"Grim","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026041420191762200_dgae145-B21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11906-004-0045-1","article-title":"Evolution of diagnostic criteria for primary aldosteronism: why is it more common in \u201cdrug-resistant\u201d hypertension today?","volume":"6","author":"Grim","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"2026041420191762200_dgae145-B22","first-page":"54","article-title":"The inappropriate secretion of aldosterone associated with adrenal hyperplasia","volume":"42","author":"Grim","year":"1976","journal-title":"Univ Mich Med Cent J"},{"issue":"9","key":"2026041420191762200_dgae145-B23","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026041420191762200_dgae145-B24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026041420191762200_dgae145-B25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"2","key":"2026041420191762200_dgae145-B26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/clinem\/dgac654","article-title":"Exclusion tests in unilateral primary aldosteronism (ExcluPA) study","volume":"108","author":"Zhu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026041420191762200_dgae145-B27","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/HYPERTENSIONAHA.122.19377","article-title":"Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis","volume":"79","author":"Leung","year":"2022","journal-title":"Hypertension"},{"issue":"6","key":"2026041420191762200_dgae145-B28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding Spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"11","key":"2026041420191762200_dgae145-B29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism\u2014a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2026041420191762200_dgae145-B30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/M17-2237","article-title":"Subclinical primary aldosteronism","volume":"167","author":"Adlin","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026041420191762200_dgae145-B31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tem.2021.10.002","article-title":"Pathophysiology and histopathology of primary aldosteronism","volume":"33","author":"Williams","year":"2022","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2026041420191762200_dgae145-B32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/HYPERTENSIONAHA.111.00662","article-title":"Abnormal aldosterone physiology and cardiometabolic risk factors","volume":"61","author":"Vaidya","year":"2013","journal-title":"Hypertension"},{"issue":"1","key":"2026041420191762200_dgae145-B33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026041420191762200_dgae145-B34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The Spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026041420191762200_dgae145-B35","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the Spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"issue":"4","key":"2026041420191762200_dgae145-B36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"issue":"1","key":"2026041420191762200_dgae145-B37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"issue":"24","key":"2026041420191762200_dgae145-B38","doi-asserted-by":"crossref","first-page":"e023082","DOI":"10.1161\/JAHA.121.023082","article-title":"Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: a collaborative study","volume":"10","author":"Hu","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2026041420191762200_dgae145-B39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"2026041420191762200_dgae145-B40","doi-asserted-by":"crossref","first-page":"155593","DOI":"10.1016\/j.metabol.2023.155593","article-title":"Renin-independent aldosteronism and chronic kidney disease in diabetes: observational and Mendelian randomization analyses","volume":"145","author":"Hu","year":"2023","journal-title":"Metab Clin Exp"},{"issue":"2","key":"2026041420191762200_dgae145-B41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2023","journal-title":"Circulation"},{"key":"2026041420191762200_dgae145-B42","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"2026041420191762200_dgae145-B43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabet Endocrinol"},{"issue":"3","key":"2026041420191762200_dgae145-B44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"issue":"4","key":"2026041420191762200_dgae145-B45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"issue":"10","key":"2026041420191762200_dgae145-B46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"issue":"22","key":"2026041420191762200_dgae145-B47","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2026041420191762200_dgae145-B48","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a scientific statement from the American Heart Association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"issue":"5","key":"2026041420191762200_dgae145-B49","doi-asserted-by":"crossref","first-page":"e2027","DOI":"10.1210\/clinem\/dgab924","article-title":"The saline infusion test for primary aldosteronism: implications of immunoassay inaccuracy","volume":"107","author":"Eisenhofer","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026041420191762200_dgae145-B50","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1210\/jc.2018-01394","article-title":"Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism","volume":"103","author":"Stowasser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026041420191762200_dgae145-B51","doi-asserted-by":"crossref","first-page":"dgz150","DOI":"10.1210\/clinem\/dgz150","article-title":"Diagnosis of primary aldosteronism by seated saline suppression test-variability between immunoassay and HPLC-MS\/MS","volume":"105","author":"Thuzar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026041420191762200_dgae145-B52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2026041420191762200_dgae145-B53","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"2026041420191762200_dgae145-B54","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1161\/HYPERTENSIONAHA.123.20536","article-title":"Who and how should we screen for primary aldosteronism?","volume":"80","author":"Funder","year":"2023","journal-title":"Hypertension"},{"issue":"13","key":"2026041420191762200_dgae145-B55","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCULATIONAHA.123.064318","article-title":"Early implementation of aldosterone-targeted therapy in patients with hypertension","volume":"147","author":"Pitt","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"2026041420191762200_dgae145-B56","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.116.07214","article-title":"Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism","volume":"68","author":"Cornu","year":"2016","journal-title":"Hypertension"},{"issue":"7","key":"2026041420191762200_dgae145-B57","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jch.12342","article-title":"High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false-positive diagnoses","volume":"16","author":"Kline","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"2026041420191762200_dgae145-B58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/HYPERTENSIONAHA.123.21983","article-title":"Long-Term follow-up of patients with elevated aldosterone-to-renin ratio but negative confirmatory test: the progression of primary aldosteronism phenotypes","volume":"81","author":"Buffolo","year":"2024","journal-title":"Hypertension"},{"issue":"1","key":"2026041420191762200_dgae145-B59","doi-asserted-by":"crossref","first-page":"lvac003","DOI":"10.1093\/ejendo\/lvac003","article-title":"Saline suppression to distinguish the primary aldosteronism subtype: a diagnostic study","volume":"188","author":"Hashimura","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026041420191762200_dgae145-B60","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/clinem\/dgac679","article-title":"Intra-individual variability of Serum aldosterone and implications for primary aldosteronism screening","volume":"108","author":"Maciel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026041420191762200_dgae145-B61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1210\/clinem\/dgac568","article-title":"Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism","volume":"108","author":"Ng","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026041420191762200_dgae145-B62","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"2026041420191762200_dgae145-B63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ajh\/hpaa151","article-title":"Variability of aldosterone measurements during adrenal venous sampling for primary aldosteronism","volume":"34","author":"Yozamp","year":"2021","journal-title":"Am J Hypertens"},{"issue":"6","key":"2026041420191762200_dgae145-B64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ejendo\/lvad159","article-title":"Postoperative ACTH-stimulated aldosterone predicts biochemical outcome in primary aldosteronism","volume":"189","author":"Bruedgam","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026041420191762200_dgae145-B65","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1210\/jc.2015-1268","article-title":"Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension","volume":"100","author":"Markou","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026041420191762200_dgae145-B66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fendo.2016.00040","article-title":"The potential of ACTH in the genesis of primary aldosteronism","volume":"7","author":"Funder","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026041420191762200_dgae145-B67","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"issue":"11","key":"2026041420191762200_dgae145-B68","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1365-2362.2011.02531.x","article-title":"High prevalence of autonomous aldosterone secretion among patients with essential hypertension","volume":"41","author":"Gouli","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"2026041420191762200_dgae145-B69","doi-asserted-by":"crossref","first-page":"644382","DOI":"10.3389\/fendo.2021.644382","article-title":"Aldosterone-Regulating receptors and aldosterone-driver somatic mutations","volume":"12","author":"Lim","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026041420191762200_dgae145-B70","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1210\/jc.2008-1340","article-title":"Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma","volume":"94","author":"Lampron","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026041420191762200_dgae145-B71","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1210\/clinem\/dgaa703","article-title":"Aldosterone is aberrantly regulated by Various stimuli in a high proportion of patients with primary aldosteronism","volume":"106","author":"St-Jean","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026041420191762200_dgae145-B72","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/EJE-08-0711","article-title":"Screening for membrane hormone receptor expression in primary aldosteronism","volume":"160","author":"Zwermann","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2026041420191762200_dgae145-B73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fendo.2016.00072","article-title":"Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism","volume":"7","author":"El Ghorayeb","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026041420191762200_dgae145-B74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1210\/endo-105-2-327","article-title":"The role of calcium in the stimulation of aldosterone production by adrenocorticotropin, angiotensin II, and potassium in isolated glomerulosa cells","volume":"105","author":"Fakunding","year":"1979","journal-title":"Endocrinology"},{"issue":"6","key":"2026041420191762200_dgae145-B75","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2026041420191762200_dgae145-B76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.34067\/KID.0006762021","article-title":"Extrarenal effects of aldosterone on potassium homeostasis","volume":"3","author":"Palmer","year":"2022","journal-title":"Kidney360"},{"issue":"2","key":"2026041420191762200_dgae145-B77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1677\/joe.0.1100315","article-title":"Unique calcium dependencies of the activating mechanism of the early and late aldosterone biosynthetic pathways in the rat","volume":"110","author":"Schiebinger","year":"1986","journal-title":"J Endocrinol"},{"issue":"12","key":"2026041420191762200_dgae145-B78","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"6","key":"2026041420191762200_dgae145-B79","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"issue":"17","key":"2026041420191762200_dgae145-B80","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"2026041420191762200_dgae145-B81","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/HYPERTENSIONAHA.117.09078","article-title":"Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay","volume":"70","author":"Morimoto","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"2026041420191762200_dgae145-B82","doi-asserted-by":"crossref","first-page":"bvac049","DOI":"10.1210\/jendso\/bvac049","article-title":"Recalibrating interpretations of aldosterone assays across the physiologic range: immunoassay and liquid chromatography-tandem mass spectrometry measurements under multiple controlled conditions","volume":"6","author":"Brown","year":"2022","journal-title":"J Endocr Soc"},{"issue":"7","key":"2026041420191762200_dgae145-B83","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1097\/HJH.0000000000001735","article-title":"Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration","volume":"36","author":"Baron","year":"2018","journal-title":"J Hypertens"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae145\/57138045\/dgae145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2220\/58769816\/dgae145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/9\/2220\/58769816\/dgae145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:38:10Z","timestamp":1776213490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/9\/2220\/7623631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae145","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,7]]}}}